Crown Bioscience names Dr Leon Hall VP of Global Scientific Excellence

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced the appointment of Dr Leon Hall as VP of Global Scientific Excellence.

In his new role, Dr Hall will be responsible for overseeing global R&D programmes and advancing Crown Bioscience's scientific excellence initiatives.

Dr Jean-Pierre Wery, Crown Bioscience CEO, said: "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services. His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global biopharmaceutical market worldwide."

Dr Hall said: "I am excited about contributing to the expansion of Crown Bioscience's translational technology platform at a higher level. I look forward to continuing Crown Bioscience's commitment to quality and scientific integrity embedded throughout the global organisation."

Dr Hall previously served as Crown Bioscience's Senior Scientific Director and led Crown Bioscience's Global Scientific Excellence Initiative.

Dr Hall established the Global Quality Council and the Global Scientific Councils that govern Crown Bioscience's research. His efforts have ensured global standards of excellence, harmonization and fostered collaborations in scientific innovation and R&D.

Hall holds a PhD from the University of Leicester, England, in Molecular Pathology and Toxicology. He has more than 15 years of preclinical rodent research experience and is considered an industry leader in the application of humanised mouse models in immunology and immuno-oncology.

Companies